SCHEMBL3913563

SCHEMBL3913563

COc1cc2c(Oc3ccc(-c4cnc(N(C)C5CC5)n(C)c4=O)cc3F)ccnc2cc1OCCCN1CCOCC1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.72
MST1R Q04912 6/20 0.72
EGFR P00533 5/20 0.72
HGF P14210 4/20 0.72
RPS6KB1 P23443 4/20 0.72
KDR P35968 4/20 0.72
TEK Q02763 4/20 0.72
BTK Q06187 4/20 0.72
FLT4 P35916 3/20 0.72
AURKA O14965 3/20 0.72
LCK P06239 3/20 0.72
CSF1R P07333 2/20 0.72
JAK2 O60674 2/20 0.71
FLT1 P17948 2/20 0.71
FGFR2 P21802 2/20 0.71
AXL P30530 6/20 0.61
MAPK9 P45984 2/20 0.56
RPS6KA5 O75582 1/20 0.56
PIM1 P11309 1/20 0.56
SRC P12931 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3917426 0.89 MET (0.77) METMST1REGFRHGFRPS6KB1
SCHEMBL3913569 0.86 MET (0.79) METMST1REGFRHGFRPS6KB1
SCHEMBL3917599 0.85 MET (0.81) METMST1REGFRHGFRPS6KB1
SCHEMBL2861036 0.84 MET (0.80) METMST1REGFRHGFRPS6KB1
SCHEMBL29376383 0.84 MET (1.00) METMST1REGFRHGFRPS6KB1
SCHEMBL15426772 0.84 MET (1.00) METMST1REGFRHGFRPS6KB1
SCHEMBL1565046 0.84 MET (1.00) METMST1REGFRHGFRPS6KB1
SCHEMBL2861831 0.84 MET (0.88) METMST1REGFRHGFRPS6KB1
SCHEMBL2869076 0.83 MET (1.00) METMST1REGFRHGFRPS6KB1
SCHEMBL2868047 0.83 MET (1.00) METMST1REGFRHGFRPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US disclosed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 EP disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE TK1, ABL1, ROR1 MET 563/4885MST1R 413/4885EGFR 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.